Please assess the completion status of the following clinical trial:

Trial Title: Genetic Basis for Prediction of Non-responders to Dietary Plant Sterol Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C concentration \>3.0 and \<4.9 mmol/L~* Fasting glucose concentration \<6.1 mmol/L~* Fasting triglyceride concentration \<4.52 mmol/L~* Genoset required: ; ApoE ε3/ε3 CYP7A1 rs3808607 T/T (n=20); ApoE ε3/ε3 CYP7A1 rs3808607 G/- (n=22); ApoE ε4/- CYP7A1 rs3808607 -/- (n=22)~Exclusion Criteria:~* Consuming, or have consumed in the last 3 months, medications or nutritional supplements which are known to affect lipid metabolism (such as cholestyramine, colestipol, niacin, clofibrate, gemfibrozil, probucol, HMG-CoA R inhibitors, methotrexate, high dose dietary supplements, fish oil capsules or plant sterol or stanol), or have any dietary restrictions which would prevent them from consuming the trial treatments~* BMI \>40~* Must not have self-reported weight gain or loss greater than 3 kg in the past three months~* Phytosterolemic~* History of active cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attacks, anemia, abnormal electrolytes, proteinuria, and abnormal liver, kidney or thyroid function~* Type 1 or type 2 diabetes, a history of cancer or malignancy in the last 5 years, or any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which could interfere with the results of the study or the safety of the participant.~* Uncontrolled hypertension having systolic blood pressure \>160mm Hg or diastolic blood pressure \>100mm Hg~* Smoker, tobacco/snuff/nicotine users, recreational drug users~* Consume more than 14 alcoholic beverages a week~* Participants who are pregnant or plan to become pregnant during the trial period or lactating mothers~* Participants will be excluded if they have clinically significant biochemistry defined as: LDL-C \<3.0mmol/L or \>4.9 mmol/L; TC \> 6.2 mmol/L; fasting glucose: \> 6.1 mmol/ l, fasting TG \>4.52 mmol/L; AST \>100 U/L; ALT \>100 U/L or or any other clinically significant abnormality in hematology and/or biochemistry at the investigator's discretion~* Patients with unstable or serious illness, for example, dementia, terminal illness, recent bereavement, recent significant medical diagnosis will also be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Plant sterols (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).